Article Details
Retrieved on: 2024-09-18 14:27:09
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In this 12-week Phase IIa study, ISM001-055 met its primary endpoint of safety and tolerability across all dose levels. (IMAGE). InSilico Medicine. In ...
Article found on: www.eurekalert.org
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here